Cdk5R1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The CDK5R1 gene (Cyclin-Dependent Kinase 5 Regulatory Subunit 1) encodes the p35 protein, a neuronal-specific activator of cyclin-dependent kinase 5 (CDK5). p35 is critical for neuronal development, synaptic plasticity, and cognitive function. Dysregulation of the p35/CDK5 pathway has been implicated in several neurodegenerative diseases, particularly Alzheimer's disease.
| Attribute |
Value |
| Symbol |
CDK5R1 |
| Full Name |
Cyclin-Dependent Kinase 5 Regulatory Subunit 1 |
| Chromosomal Location |
17q11.2 |
| NCBI Gene ID |
8851 |
| Ensembl ID |
ENSG00000108395 |
| UniProt |
Q15078 |
The p35 protein (350 amino acids) contains:
- An N-terminal myristoylation site for membrane targeting
- A regulatory domain that binds and activates CDK5
- A p10 cleavage product generated by calpain proteolysis
The p35 protein serves as the primary neuronal activator of CDK5. Key functions include:
- CDK5 Activation: p35 forms a heterodimer with CDK5, activating its kinase activity
- Neuronal Development: Regulates neuronal migration, axon guidance, and synapse formation
- Synaptic Plasticity: Modulates AMPA receptor trafficking and long-term potentiation (LTP)
- Cytoskeletal Regulation: Phosphorylates tau, MAP1B, and neurofilaments
CDK5R1 is predominantly expressed in post-mitotic neurons throughout the brain, with highest expression in:
Expression peaks during embryonic development and remains high in adult brain.
- p35 is cleaved to p25 in AD brains, leading to hyperactive CDK5
- p25 accumulation causes tau hyperphosphorylation and neurofibrillary tangle formation
- CDK5/p25 activity contributes to synaptic loss and cognitive decline
- PMID:14597658, PMID:14749363, PMID:15162105
- CDK5 phosphorylates LRRK2, modulating its kinase activity
- CDK5/p35 pathway intersects with dopaminergic signaling
- Animal models show protection with CDK5 inhibitors
- PMID:17452840, PMID:19794439
- Dysregulated CDK5 activity in motor neurons
- Interacts with TDP-43 pathology
- Contributes to cytoskeletal disruption
- PMID:20665475
- Frontotemporal dementia: Tau phosphorylation by CDK5
- Huntington's disease: Abnormal CDK5 regulation
- Multiple sclerosis: Demyelination involvement
- PMID:19855041, PMID:20629637
- Roscovitine: CDK5 inhibitor in clinical trials for cancer, potential for AD
- Alogliptin: DPP-4 inhibitor with CDK5 modulatory activity
- Challenges: Brain penetration, toxicity concerns
- Calpain inhibitors: Prevent p25 generation
- Gene therapy: Restore proper p35/CDK5 balance
- Small molecule modulators: Allosteric modulators of the p35-CDK5 interaction
- p35 knockout mice: Developmental lethality, neuronal migration defects
- p25 transgenic mice: Induces tau pathology, cognitive deficits
- Conditional p25 mice: Reversible AD-like phenotype
The study of Cdk5R1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:14597658 - CDK5 in tau pathogenesis
- PMID:14749363 - p25 generation in AD
- PMID:15162105 - CDK5 and synaptic plasticity
- PMID:17452840 - CDK5 in PD models
- PMID:19794439 - LRRK2 phosphorylation by CDK5
- PMID:20665475 - CDK5 in ALS
- PMID:19855041 - CDK5 in HD
- PMID:20629637 - CDK5 in FTD